Evidence map›Paper›PMID 41450962›Full record

ArticleFrontiers in molecular biosciences2025

Diagnostic utility of IBEX Bone Health for assessment of osteoporosis from knee radiographs.

Robert Meertens, Ben Lopez, Mike Gundry, Ben Crone, Wavell Vigers, Michelle Evans, Richard McWilliam, Sarah Jarvis

Abstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Robert MeertensDepartment of Health and Care Professions, University of Exeter, Exeter, United Kingdom.
Ben LopezIbex Innovations Ltd., Sedgefield, United Kingdom.
Mike GundryDepartment of Health and Care Professions, University of Exeter, Exeter, United Kingdom.
Ben CroneIbex Innovations Ltd., Sedgefield, United Kingdom.
Wavell VigersDepartment of Health and Care Professions, University of Exeter, Exeter, United Kingdom.
Michelle EvansDepartment of Health and Care Professions, University of Exeter, Exeter, United Kingdom.
Richard McWilliamIbex Innovations Ltd., Sedgefield, United Kingdom.
Sarah JarvisIbex Innovations Ltd., Sedgefield, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study reports testing of IBEX Bone Health (IBEX BH) software, applied following acquisition of knee digital radiographs (DRs). IBEX BH analyses the DR to measure areal bone mineral density (aBMD) and T-scores. This study investigates aBMD and T-score at the knee as a biomarker to identify patients at high risk of osteoporosis. Methods: A 497-participant single-centre, non-randomised, prospective study was carried out comparing a) IBEX BH, a quantitative digital radiography software device, to b) Dual-energy X-ray Absorptiometry (DXA). Participants underwent left and right knee DRs, and knee, pelvis and lumbar spine DXA scans. Analysis evaluates the efficacy of IBEX BH as a knee densitometry device, comparing performance to that of reference standard DXA at the same anatomical site. It further evaluates the area under the receiver operating characteristics curve (AUC) performance of IBEX BH in predicting osteoporosis, defined by clinical reports from hip and/or spine DXA. This is compared against DXA referral recommendations derived from National Osteoporosis Guideline Group (NOGG) guidelines, which use 10-year fracture risk calculated by the fracture risk assessment tool (FRAX) without neck of femur (NoF) aBMD. Results: Correlations between IBEX BH aBMD and DXA aBMD at the same anatomical sites were 0.91 (95% confidence interval (CI) [0.90, 0.93]) for the proximal tibia (PT) and 0.87 (95%CI [0.84, 0.89]) for the distal femur (DF). For the PT and DF, the AUC for IBEX BH for discriminating central osteoporosis was 0.91 (95%CI [0.87, 0.95]) and 0.88 (95%CI [0.82, 0.93]) respectively, compared to 0.93 (95%CI [0.9, 0.97]) and 0.92 (95%CI [0.88, 0.96]) for DXA. In operating point analysis, the sensitivity and specificity to central osteoporosis of PT IBEX BH T-score was 0.66 95%CI [0.50, 0.78] and 0.94 95%CI [0.89, 0.96] respectively, compared to a sensitivity and specificity of 0.66 95%CI [0.50, 0.79] and 0.69 95%CI [0.63, 0.75] respectively for NOGG referral thresholds based on FRAX without NoF aBMD. Conclusion: Ibex BH shows strong correlation to DXA at the same anatomical site, and superior ability to FRAX without NoF aBMD for classifying central osteoporosis. Results demonstrate the potential utility of IBEX BH as a densitometer and opportunistic osteoporosis screening tool.

Indexed as

artificial intelligencebone mineral densitydistal femurknee radiographsopportunistic screeningosteoporosisproximal tibia

Identifiers

PMID41450962
PMCPMC12728432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.